[1] |
WOLFENDER JL, LITAUDON M, TOUBOUL D, et al. Innovative omics-based approaches for prioritisation and targeted isolation of natural products-new strategies for drug discovery[J]. Nat Prod Rep, 2019, 36(6): 855-868.
|
[2] |
KHAN H, SAEEDI M, NABAVI SM, et al. Glycosides from medicinal plants as potential anticancer agents: Emerging trends towards future drugs[J]. Curr Med Chem, 2019, 26(13): 2389-2406.
|
[3] |
杨云松, 高鹏, 代龙. 糖苷类化合物体外生物转化的研究进展[J]. 中国生化药物杂志, 2012, 32(6): 927-930.
|
[4] |
SPANOGIANNOPOULOS P, BESS EN, CARMODY RN, et al. The microbial pharmacists within us: A metagenomic view of xenobiotic metabolism[J]. Nat Rev Microbiol, 2016, 14(5): 273-287.
|
[5] |
RYE CS, WITHERS SG. Glycosidase mechanisms[J]. Curr Opin Chem Biol, 2000, 4(5): 573-580.
|
[6] |
PRASSAS I, DIAMANDIS EP. Novel therapeutic applications of cardiac glycosides[J]. Nat Rev Drug Discov, 2008, 7(11): 926-935.
|
[7] |
ZHANG J, PONOMAREVA LV, NANDURKAR NS, et al. Influence of sugar amine regiochemistry on digitoxigenin neoglycoside anticancer activity[J]. ACS Med Chem Lett, 2015, 6(10): 1053-1058.
|
[8] |
LAURSEN M, GREGERSEN JL, YATIME L, et al. Structures and characterization of digoxin-and bufalin-bound Na+, K+-ATPase compared with the ouabain-bound complex[J]. Proc Natl Acad Sci USA, 2015, 112(6): 1755-1760.
|
[9] |
HUANG W, WEN C, ZHOU ZR, et al. An efficient one-pot enzymatic synthesis of cardiac glycosides with varied sugar chain lengths[J]. Adv Synth Catal, 2019, 361(13): 3114-3119.
|
[10] |
于荣敏. 天然药物活性成分的生物合成与生物转化[J]. 中草药, 2006, 37(9): 1281-1288.
|
[11] |
穆丽华, 刘屏, 张静. 皂苷体外生物转化水解反应的研究进展[J]. 天然产物研究与开发, 2016, 28(1): 156-163.
|
[12] |
范冬冬, 匡艳辉, 向世勰, 等. 绞股蓝化学成分及其药理活性研究进展[J]. 中国药学杂志, 2017, 52(5): 342-352.
|
[13] |
王宇. 生物转化法制备人参皂苷F1及Rh1的研究[D]. 大连: 大连工业大学, 2015.
|
[14] |
MCDONALD AG, BOYCE S, TIPTON KF. ExplorEnz: the primary source of the IUBMB enzyme list[J]. Nucleic Acids Res, 2009, 37(S1): D593-D597.
|
[15] |
LOMBARD V, GOLACONDA RAMULU H, DRULA E, et al. The carbohydrate-active enzymes database (CAZy) in 2013[J]. Nucleic Acids Res, 2014, 42: 490-495.
|
[16] |
黄红卫, 刘艳丽, 李春. 糖苷酶的研究及其改造策略[J]. 生物技术通报, 2010(5): 55-60.
|
[17] |
崔莹莹. 酶法分离和转化人参皂苷Rb2、Rb3和Rc的研究[D]. 长春: 东北师范大学, 2019.
|
[18] |
SHIN KC, OH DK. Classification of glycosidases that hydrolyze the specific positions and types of sugar moieties in ginsenosides[J]. Crit Rev Biotechnol, 2016, 36(6): 1036-1049.
|
[19] |
NOH KH, OH DK. Production of the rare ginsenosides compound K, compound Y, and compound Mc by a thermostable beta-glycosidase from Sulfolobus acidocaldarius<\i>[J]. Biol Pharm Bull, 2009, 32(11): 1830-1835.
|
[20] |
TAWAB MA, BAHR U, KARAS M, et al. Degradation of ginsenosides in humans after oral administration[J]. Drug Metab Dispos, 2003, 31(8): 1065-1071.
|
[21] |
HASEGAWA H. Proof of the mysterious efficacy of ginseng: Basic and clinical trials: Metabolic activation of ginsenoside: Deglycosylation by intestinal bacteria and esterification with fatty acid[J]. J Pharmacol Sci, 2004, 95(2): 153-157.
|
[22] |
刘文山,李振伟,傅荣昭. 糖苷酶在人参皂苷转化中的应用[J]. 生物技术通讯, 2019, 30(4): 579-588.
|
[23] |
姜彬慧, 韩颖, 赵余庆, 等. 酶转化三七叶总皂苷制备人参皂苷C-K的工艺优化[J]. 中草药, 2004, 35(9): 986-988.
|
[24] |
童庆宣, 陈良华, 明艳林, 等. 稀有人参皂苷IH901酶法转化与制备研究[J]. 天然产物研究与开发, 2009, 21(6): 1039-1044.
|
[25] |
张阳, 林毅. 酶法转化二醇型人参皂苷Rd及制备稀有人参皂苷C-K[J]. 华侨大学学报(自然科学版), 2011, 32(6): 668-671.
|
[26] |
于兆慧, 刘其媛, 崔莉, 等. 蜗牛酶转化人参皂苷Rb1制备人参稀有皂苷Compound K的研究[J]. 中华中医药杂志, 2015, 30(2): 412-416.
|
[27] |
羊学荣, 卢凤来, 王磊, 等. 酶水解百分之五十罗汉果皂苷Ⅴ方法学研究[J]. 广西植物, 2015, 35(6): 812-816, 898.
|
[28] |
卢文杰, 王雪芬, 陈家源, 等. 大叶紫金牛化学成分的研究[J]. 华西药学杂志, 1990, 5(3): 136-138.
|
[29] |
ZHENG ZF, XU JF, FENG ZM, et al. Cytotoxic triterpenoid saponins from the roots of Ardisia crenata<\i>[J]. J Asian Nat Prod Res, 2008, 10(9/10): 833-839.
|
[30] |
CHANG X, LI W, JIA Z, et al. Biologically active triterpenoid saponins from Ardisia japonica<\i>[J]. J Nat Prod, 2007, 70(2): 179-187.
|
[31] |
熊剑, 章翔, 程光, 等. Ardipusilloside Ⅰ诱导胶质母细胞瘤细胞凋亡实验研究[J]. 中华神经外科疾病研究杂志, 2010, 9(1): 10-14.
|
[32] |
张静. 走马胎中三萜皂苷Ag3的生物转化及其产物抗肿瘤活性研究[D]. 太原: 山西中医学院, 2016.
|
[33] |
LIU W, HUANG W, SUN WL, et al. Production of diosgenin from yellow ginger (Dioscorea zingiberensis<\i> C. H. Wright) saponins by commercial cellulase[J]. World J Microbiol Biotechnol, 2010, 26(7): 1171-1180.
|
[34] |
夏广萍, 刘鹏, 赵娜夏, 等. β<\i>-葡萄糖苷酶水解黄芪甲苷的研究[J]. 中草药, 2012, 43(6): 1112-1114.
|
[35] |
王霄旸, 谢人明, 孙文基. 淫羊藿属药用植物黄酮类化合物的研究进展[J]. 中药药理与临床, 2010, 26(5): 171-175.
|
[36] |
于霄, 宋静, 熊志立, 等. 一测多评法测定淫羊藿中朝藿定A、朝藿定B、朝藿定C及淫羊藿苷的含量[J]. 中国中药杂志, 2010, 35(24): 3310-3313.
|
[37] |
贾东升, 贾晓斌, 赵江丽, 等. 纤维素酶转化淫羊藿苷制备宝藿苷Ⅰ的研究[J]. 中草药, 2010, 41(6): 888-892.
|
[38] |
张振海, 陈玲玲, 贾晓斌, 等. β<\i>-葡萄糖苷酶酶解淫羊藿苷制备宝藿苷Ⅰ的工艺研究[J]. 中国药房, 2011, 22(43): 4059-4061.
|
[39] |
贾东升, 贾晓斌, 薛璟, 等. 蜗牛酶转化淫羊藿苷制备淫羊藿苷元的研究[J]. 中国中药杂志, 2010, 35(7): 857-860.
|
[40] |
徐凤娟, 孙娥, 张振海, 等. 纤维素酶转化朝藿定B制备箭藿苷B的研究[J]. 中国中药杂志, 2014, 39(2): 235-239.
|
[41] |
高霞, 刘璇, 陈彦, 等. 淫羊藿总黄酮的生物转化过程分析[J]. 中国中药杂志, 2013, 38(23): 4079-4083.
|
[42] |
彭静, 马益华, 陈彦, 等. 固定化蜗牛酶同时生物转化淫羊藿中4种黄酮苷[J]. 中成药, 2016, 38(9): 1984-1990.
|
[43] |
卢艺. 基于酶水解制备淫羊藿次级黄酮苷的研究[D]. 镇江: 江苏大学, 2019.
|
[44] |
BIAN X, WANG S, LIU J, et al. Hepatoprotective effect of chiisanoside against acetaminophen-induced acute liver injury in mice[J]. Nat Prod Res, 2019, 33(18): 2704-2707.
|
[45] |
BIAN X, LIU X, LIU J, et al. Study on antidepressant activity of chiisanoside in mice[J]. Int Immunopharmacol, 2018, 57: 33-42.
|
[46] |
BIAN XB, ZHAO Y, GUO X, et al. Chiisanoside, a triterpenoid saponin, exhibits anti-tumor activity by promoting apoptosis and inhibiting angiogenesis[J]. RSC Adv, 2017, 7(66): 41640-41650.
|
[47] |
陈晨. Chiisanoside次级苷的分离、制备及其抗心律失常活性研究[D]. 长春:吉林农业大学, 2020.
|